Number of suitable people: CDEC discussed the uncertainty in the number of patients with reasonably intense to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some clients that are categorized as possessing mild or average disorder could possibly have a critical bl